CXCL12-CXCR4/CXCR7 Axis in Colorectal Cancer: Therapeutic Target in Preclinical and Clinical Studies.
CXCL12-CXCR4/CXCR7 Axis in Colorectal Cancer: Therapeutic Target in Preclinical and Clinical Studies.
复制标题
结直肠癌中的CXCL12-CXCR4/CXCR7轴：临床前和临床研究的治疗靶点。
DOI：
10.3390/ijms22147371
复制
发表时间：
2021-07-09
影响因子：
5.6
通讯作者：
Khare S
中科院分区：
文献类型：
--
作者：
Khare T;Bissonnette M;Khare S
趋化因子是趋化性细胞因子，可促进癌症生长、转移并调节对化疗的耐药性。基质细胞衍生因子1（SDF 1）也称为C-X-C基序趋化因子12（CXCL 12），是一种预后因子，是一种细胞外稳态趋化因子，是趋化因子受体C-X-C趋化因子受体4型（CXCR 4）的天然配体，也称为融合素或分化簇184（CD 184）和趋化因子受体7型（CXCR 7）。CXCR 4是最广泛表达的视紫红质样G蛋白偶联趋化因子受体（GPCR）。CXCL 12-CXCR 4轴参与结直肠癌（CRC）中的肿瘤生长、侵袭、血管生成和转移。CXCR 7，最近被称为非典型趋化因子受体3（ACKR 3），是G蛋白偶联细胞表面受体家族中的一员，也常在多种癌细胞中表达。CXCR 7与CXCR 4一样，调节免疫、血管生成、干细胞运输、细胞生长和器官特异性转移。CXCR 4和CXCR 7根据肿瘤类型单独或一起表达。当一起表达时，CXCR 4和CXCR 7可以形成同源或异源二聚体。CXCL 12及其受体CXCR 4和CXCR 7的同源和异源二聚化改变它们的信号传导活性。只有少数药物已被批准用于临床使用靶向CXCL 12-CXCR 4/CXCR 7轴。几种CXCR 4抑制剂在实体瘤治疗的临床试验中取得了有限的成功，而CXCR 7特异性抑制剂仍在CRC的临床前研究中。本文综述了趋化因子CXCL 12及其受体CXCR 4和CXCR 7的最新研究进展，重点介绍了靶向CXCL 12-CXCR 4/CXCR 7轴作为结直肠癌治疗策略。
Chemokines are chemotactic cytokines that promote cancer growth, metastasis, and regulate resistance to chemotherapy. Stromal cell-derived factor 1 (SDF1) also known as C-X-C motif chemokine 12 (CXCL12), a prognostic factor, is an extracellular homeostatic chemokine that is the natural ligand for chemokine receptors C-X-C chemokine receptor type 4 (CXCR4), also known as fusin or cluster of differentiation 184 (CD184) and chemokine receptor type 7 (CXCR7). CXCR4 is the most widely expressed rhodopsin-like G protein coupled chemokine receptor (GPCR). The CXCL12–CXCR4 axis is involved in tumor growth, invasion, angiogenesis, and metastasis in colorectal cancer (CRC). CXCR7, recently termed as atypical chemokine receptor 3 (ACKR3), is amongst the G protein coupled cell surface receptor family that is also commonly expressed in a large variety of cancer cells. CXCR7, like CXCR4, regulates immunity, angiogenesis, stem cell trafficking, cell growth and organ-specific metastases. CXCR4 and CXCR7 are expressed individually or together, depending on the tumor type. When expressed together, CXCR4 and CXCR7 can form homo- or hetero-dimers. Homo- and hetero-dimerization of CXCL12 and its receptors CXCR4 and CXCR7 alter their signaling activity. Only few drugs have been approved for clinical use targeting CXCL12-CXCR4/CXCR7 axis. Several CXCR4 inhibitors are in clinical trials for solid tumor treatment with limited success whereas CXCR7-specific inhibitors are still in preclinical studies for CRC. This review focuses on current knowledge of chemokine CXCL12 and its receptors CXCR4 and CXCR7, with emphasis on targeting the CXCL12–CXCR4/CXCR7 axis as a treatment strategy for CRC.
登录
查看更多内容
影响因子：
4.2
作者：
Chen, Yuhui;Teng, Fei;Nie, Zhiyu
通讯作者：
Nie, Zhiyu
影响因子：
5.6
作者：
Conciatori F;Bazzichetto C;Falcone I;Pilotto S;Bria E;Cognetti F;Milella M;Ciuffreda L
通讯作者：
Ciuffreda L
DOI：
10.1084/jem.187.12.2009
发表时间：
1998-06-15
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
Cole KE;Strick CA;Paradis TJ;Ogborne KT;Loetscher M;Gladue RP;Lin W;Boyd JG;Moser B;Wood DE;Sahagan BG;Neote K
通讯作者：
Neote K
影响因子：
37.3
作者：
Duan FT;Qian F;Fang K;Lin KY;Wang WT;Chen YQ
通讯作者：
Chen YQ
影响因子：
6
作者：
Bartolome, Ruben A.;Ferreiro, Sergio;Teixido, Joaquin
通讯作者：
Teixido, Joaquin